6533b827fe1ef96bd128700f
RESEARCH PRODUCT
Tapentadol in cancer pain management: a prospective open-label study.
Federica AielliGiampiero PorzioSebastiano MercadanteClaudio AdileCasuccio AlessandraAntonello GiarratanoCorrado FicorellaPatrizia Ferrerasubject
MaleSettore MED/41 - AnestesiologiaPainNeuropathic painCancer pain Neuropathic pain Opioids Tapentadol AnalgesiaQuality of lifePhenolsNeoplasmsMedicineCancer pain; Neuropathic pain; Opioids; Tapentadol; Aged; Analgesics; Female; Humans; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Phenols; Prospective Studies; Medicine (all)HumansProspective StudiesCancer painAdverse effectProspective cohort studyAgedPain MeasurementAnalgesicsbusiness.industryMedicine (all)General MedicineMiddle AgedTapentadolClinical trialOpioidsTapentadolTolerabilityAnesthesiaNeuropathic painFemaleCancer painbusinessmedicine.drugdescription
OBJECTIVES: The aim of this prospective, open-label study was to evaluate the efficacy and tolerability of tapentadol (TP) in the management of cancer pain. METHODS: A 4 weeks' prospective study was carried out in 50 opioid-naive cancer patients with moderate-severe pain. Each patient initially received twice-daily doses of slow-release TP 50 mg. Doses were then managed to maintain adequate relief or dose-limiting toxicity, on the basis of the clinical response. The following parameters were recorded at weekly intervals for 4 weeks: pain and opioid-related adverse effects, quality of life measured with the Spitzer score, TP escalation index percent (TPEI%) and TP escalation index in mg (TPEImg), calculated at the end of the study, pain mechanisms, and PainDETECT at baseline. RESULTS: Of 50 patients, 39 completed the entire study and 11 discontinued the treatment for different reasons. Pain intensity significantly decreased from baseline to all the week intervals (p < 0.0005), and adverse effects did not changed significantly, while quality of life improved. TP escalation indexes were low and no relationship was found with age, gender, and pain mechanisms. CONCLUSION: Tapentalol started in doses of 100 mg/day was well-tolerated and effective in opioid-naive patients with cancer pain, regardless of the pain mechanism. It can be considered as a flexible drug to be used in patients with moderate-severe pain. LIMITATIONS: This was an open-label study for exploratory purposes. Data should be confirmed in controlled studies with a larger number of patients
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-01-01 | Current medical research and opinion |